What will happen the first time I visit an HRT clinic?
All doctors and clinics have their own individual approach but our clinic would be fairly typical.
We find it helpful for our patients to complete a brief questionnaire before consultation. This is designed to provide us with an overview of your symptoms and your expectations should you elect to start HRT.
Details of any family history of heart, bone, DVT / pulmonary embolism, or breast disease are recorded. General and pelvic examinations are important to reassure you that there are no physical problems.
There is always a choice of treatment. We discuss the potential benefits and possible problems of HRT in general and for you as an individual in particular. Each patient receives an information leaflet. If a patient is uncertain as to how she wishes to proceed we suggest that she returns in about four weeks.
How can atrophic vaginitis - dry vagina at menopause - painful sex - be treated?
What is atrophic vaginitis?
Atrophy is the partial or complete wasting away of body tissue and what is vaginitis? Vaginitis is inflammation of the vagina.
What local genital symptoms might be associated with the menopause?
After the menopause, as a result of vaginal atrophy due to loss of estrogen, vaginal dryness and discomfort are more likely to become a problem for you. Local infection, atrophic vaginitis, becomes more common now that there is less protective lactic acid and this may result in inflammation causing soreness and discharge. The vaginal dryness and inflammation may cause discomfort or even pain when you make love (dyspareunia). On occasion, the inflammation may cause bleeding. All postmenopausal bleeding must be investigated (17).
The peri menopause symptoms associated with atrophic vaginitis are:-
- Genital Dryness
- Itching
- Burning
- Dyspareunia - Painful Sex
- Burning leukorrhea
- Vulvar pruritus
- Feeling of pressure
- Yellow malodorous discharge
- Urinary
:-
- Dysuria
- Hematuria
- Urinary Frequency
- Urinary tract infection
- Stress incontinence
These atrophic vaginitis symptoms can occur as pre menopause symptoms although they are more common in post menopausal women.
How can atrophic vaginitis - dry vagina at menopause - painful sex - be treated?
Topical oestrogen (creams and pessaries) are commonly used in postmenopausal women to improve the quality of the vaginal epithelium in atrophic vaginitis. Fifteen percent of premenopausal women, 10-40% of postmenopausal women, and 10-25% of women receiving systemic hormone therapy experience urogenital atrophy. The most common symptoms are dryness, burning, pruritus, irritation, and dyspareunia (painful sexual intercourse). Topical Estrogen or hormone replacement therapy (ERT-HRT) is the treatment of choice in postmenopausal women.0101
If genital symptoms, such as vaginal dryness, pain during lovemaking or perhaps bladder symptoms are troubling you, these could be due to reduced oestrogen levels in the tissues around the genital area. These symptoms usually respond to HRT or to topical preparations (oestrogen creams or pessaries). On occasion, local symptoms may fail to respond to HRT anyway and additional topical oestrogen may be required. To begin with, the creams or pessaries are introduced each night for ten days to two weeks and then reduced to a maintenance regime varying from twice weekly to perhaps no more than once each month depending on symptoms, age and response. There are a variety of topical oestrogen preparations (Table 28.1).
Estring (Pharmacia and Upjohn), a synthetic soft rubber ring which slowly releases oestradiol can be introduced into the vagina and replaced at three monthly intervals. If the uterus is still present intermittent courses of progestogen should be considered to encourage endometrial shedding (HRT and progestogen). The ring is as effective as oestrogen creams and some women find the ring more acceptable.
Table 28.1 Topical creams and pessaries that
are commonly used in menopause treatment.
Preparation |
Oestrogen |
Company |
|
Ortho-Gynest Pessaries |
Oestriol 500 g |
Janssen-Cilag |
|
Ortho-Gynest Cream |
Oestriol 0.01% |
Janssen-Cilag |
|
Ovestin Cream |
Oestriol 0.1% |
Organon |
|
Ovestin Pessaries |
Oestradiol 1mg |
Organon |
|
Premarin Cream |
Conjugated oestrogens 625 mg |
Wyeth |
|
Vagifem Pessaries |
Oestradiol 25 microg |
Novo Nordisk |
|
Estring Ring |
Oestradiol (7.5 microg release/day) |
Pharmacia and Upjohn |
Almost invariably, unless you are taking HRT, there will be some degree of vaginal atrophy after the menopause. Quite frequently, patients are referred with vaginal discomfort and a physical examination reveals a prolapse (1). The only way to determine how much of the discomfort is due to the vaginal atrophy and how much to the prolapse is to treat the atrophy with topical (local cream or pessary) oestrogen and then reassess the symptoms.
How do we decide which will be the most appropriate HRT for me?
Figure 28.1
Figure 28.1 is a flowchart indicating the salient questions to be addressed when considering the HRT options. There are three main questions leading to the appropriate options:
First, have you had a hysterectomy ?
If your womb has been removed (hysterectomy), oestrogen replacement can be prescribed alone; there is generally no need for progestogens. If the womb has not been removed and oestrogen were prescribed unopposed, there would be a chance of the endometrium (womb lining) becoming unduly thickened with a risk of bleeding problems and on rare occasions malignancy (HRT and progestogen).?
Secondly, if your womb is still present, are you still seeing your periods?
If periods are occurring spontaneously HRT would be supplementing the natural hormone cycle. In addition to the oestrogen replacement your doctor would suggest a progestogen for 10 to 12 days each month to ensure a regular withdrawal bleed. This prevents your endometrium (lining of the womb) becoming too thick. If you have not reached your menopause and a non-bleed variety of HRT were prescribed you would almost certainly have irregular bleeding.
Finally, if your womb is still present and the menopause has already occurred, do you wish to have a regular withdrawal bleed?
There is a choice of prescribing the progestogen sequentially to produce a regular withdrawal bleed or prescribing the progestogen on a daily (non-cyclical) regimen: This continuous combined HRT provides the benefits of HRT without “periods". A blood hormone test can be arranged to provide a guide as to whether you have reached your menopause ( 14).
What side effects could I experience when I start HRT?
You will probably have no difficulties as hormone replacement therapy is simply ‘replacing’ a natural hormone deficiency.
- You may experience mastalgia (breast discomfort) initially but this usually settles quickly by itself or with pyridoxine (vitamin B6) 50mg twice daily or gamolenic acid up to 320 mg daily.
- If you have not had a hysterectomy , there may be a little spotting of blood during the first month or so.
- Around the menopause, there is a tendency to gain weight, whether you take HRT or not (Q 28.22).
What is the choice of oestrogen only preparations?
Oestrogens may be natural or synthetic although both may be manufactured.
When natural oestrogens are taken, the oestrogens in the blood are the same as would be released by the ovaries. Hormone replacement uses natural oestrogens.
After synthetic oestrogen administration, oestrogens structurally different from those released by the ovaries appear in the blood. Ethinyl oestradiol and mestranol are synthetic oestrogens used in combined oral contraceptive pills.

Estrogen Only HRT Preparations
There are several estrogen only HRT preparations. The oestrogen can be administered
- orally (tablets –Table 28.2),
- transdermally (patches –Table 28.3 and Table 28.4 or gels),
- subcutaneously as implants (Figure 28.1),
The nasal spray and vaginal ring methods have been introduced in 2001 but they were discontinued in 2006.
Table: 28. 2 Estrogen Only Tablets
|
PREPARATION |
OESTROGEN |
DOSE (mg) |
COMPANY |
|
Climaval |
Oestradiol valerate |
1 and 2 |
Novartis |
|
Elleste Solo |
Oestradiol |
1 and 2 |
Searle |
|
Harmogen |
Oestrone |
1.5 |
Pharmacia and Upjohn |
|
Hormonin |
Oestriol/Oestrone/ oestradiol |
0.27/1.4/ 0.6 |
Shire |
|
Premarin |
Conjugated Oestrogens |
0.625 and 1.25 |
Wyeth |
|
|
Oestradiol valerate |
1 and 2 |
Schering |
|
Zumenon |
Oestradiol |
1 and 2 |
Solvay |
Doctors tend to have their personal preference for first choice recommendation. As with the combined oral contraceptive pill, the acceptability and side effects for each preparation vary between patients. If you have had a recommendation from a friend or relative it would seem sensible for you to try it.
Premarin is derived from pregnant mares urine. It has been popular for many years and much of the research on HRT relates to this product. The pharmaceutical company producing Premarin has documented evidence from veterinary surgeons that there is no cruelty to the animals involved.
Women who have been deprived of oestrogen for more than a few months seem to be prone to side effects and in particular to mastalgia (breast discomfort). It is often wise, particularly if there is a history of mastalgia, to begin with a low dose preparation; the tablets can be taken every few days and gradually increased to the daily regimen.
Oestrogen tablets are broken down in the small bowel where the oestrogen is absorbed. The blood circulating through the bowel then passes to the liver where much is broken down before it has a chance to reach the rest of the body. Sometimes side effects associated with oestrogen tablets may be avoided by using skin patches or by introducing the oestradiol as an implant under the skin. Blood from the skin passes to all parts of the body and not specifically through the liver on its first-pass. Several companies produce patches of different strengths designed to release between 25 and 100 ug (micrograms)/24 hours. Most must be changed twice each week (Table 28.3).
HRT Patches
Table 28. 3 Oestradiol skin patches.
|
PREPARATION |
DOSE (mg / 24 hours) |
COMPANY |
|
Elleste Solo MX |
40 or 80 |
Searle |
|
Estraderm MX |
25, 50, 75 or 100 |
Ciba |
|
Estraderm TTS |
25, 50, or 100 |
Ciba |
|
Evorel |
25, 50, 75 or 100 |
Janssen-Cilag |
|
Fematrix |
40 or 80 |
Solvay |
|
Menorest |
37.5, 50 or 75 |
Poulenc Rorer |
Some patches are designed to be changed at weekly intervals:
Table 28. 4
|
PREPARATION |
DOSE micg / 24 hours) |
COMPANY |
|
FemSeven |
50, 75 or 100 |
Merck |
|
|
50 or 100 |
Schering |
Some women find that their patches stay in place whilst bathing but most prefer to take the patch off and replace it afterwards. Allergic reactions resulting in irritation and redness can be a problem although the more recent patches seem less likely to cause this.
There are two oestrogen gels (Oestrogel: Hoechst and Sandrena: Organon) for application to the skin. Between two and four measures of Oestrogel are rubbed gently into the upper arms, shoulders or thighs daily usually after bathing. Sandrena comes in 0.5 and 1mg sachets, and the gel is similarly applied each day.
Related Medical Abstracts - Click on the paper title:-
- Intranasal versus transdermal matrix oestrogen replacement in Australasian women. (2005-01)
- Aerodiol: the efficacy and tolerability of intranasal estrogen administration. (2003-01)
- The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
(2003-02)
- Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. (2003-03)
- Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. (2003-04)
- Pulsed estrogen therapy: relieving climacteric symptoms, preventing postmenopausal bone loss. (2002-01)
- Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. (2002-02)
- Efficacy and tolerability of pulsed estrogen therapy: a 12-week double-blind placebo-controlled study in highly symptomatic postmenopausal women. (2002-03)
- Clinical e quivalence of intranasal estradiol and oral estrogens for postmenopausal symptoms. (2002-04)
- Aerodiol versus the transdermal route: perspectives for patient preference. (2001-01)
- Dose-ranging studies of a novel intranasal estrogen replacement therapy. (2001-02)
- Randomized comparison of intranasal and transdermal estradiol. (2000-01)
- New developments in topical estrogen therapy (1997)
- Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. (2003-03)
How are oestradiol implants introduced?
Before hysterectomy, if the ovaries are to be removed, most patients would be offered a subcutaneous (under the skin) oestradiol implant.
- Subsequently, these implants are introduced on an outpatient basis under local anaesthetic.
- A half-inch incision is required and a small tube is introduced under the skin.
- The implant is then inserted down the tube.
- The wound may require one or two stitches.
- We generally make the small incision low down on the abdominal wall but some prefer them high and to the side of the buttock area.
- They may be introduced at between six- and twelve-month intervals.
- The oestradiol implants are available in 25, 50 and 100mg pellets, the largest being the size of an airgun pellet which are few millimetres long.
Figures showing insertion of oestradiol implant.

Is it possible to be given too much oestrogen?
This cannot occur if tablets, gels or patches are used according to the recommended doses.
Occasionally, there can be problems with implants. Implants may continue to release oestradiol for eighteen months or more. There is a wide variation in serum (blood) oestradiol levels following an implant. In one study, the range was between 114 and 853 pmol/l one year after a 100mg oestradiol implant.
Some patients seem to require implants relatively frequently to control their menopausal symptoms and this could result in blood levels above those experienced naturally during years when the ovaries are functioning.
If it is suspected that your blood oestradiol level could be running high although you feel that you need another implant a blood sample can be analysed.
At one time, if the blood oestradiol level proved to be high, the term tachyphylaxis was used although tachyphylaxis strictly means that symptoms seem inappropriate for normal blood levels. We now assume that the symptoms must be related to the rate of fall of oestradiol levels rather than oestrogen deficiency. In these circumstances, a 25 mg oestradiol implant can be introduced or a low dose oral preparation or transdermal patch used to relieve symptoms whilst the original implants gradually lose their activity.
Related Medical Abstracts - Click on the paper title:-
- A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms following hysterectomy and bilateral salpingo-oophorectomy. (2000-01)
- An audit of oestrogen implant hormone replacement therapy. (1998-01)
- An audit of oestradiol levels and implant Frequency in women undergoing subcutaneous implant therapy. (1995-01)
- Hormone implants and tachyphylaxis. (1990)
How long will my oestradiol implant last?
This varies from patient to patient and the strength of the implant used.
A fifty eight year old lady had her last of several oestradiol implants in 1994. She had found the implants suited her best. As she had not had a hysterectomy cyclical progestogens were required to prevent problems with the endometrium (HRT and progestogen). She then decided that she would prefer to avoid regular bleeds. We have monitored her oestrogen levels and it has taken four years for this to fall to a level where we can safely consider her for a continuous combined preparation. In our experience it is unusual for implants to function for so long.
Related Medical Abstracts - Click on the paper title:-
Why might I need progestogen in addition to oestrogen replacement?
If your uterus is present, progestogen is essential to protect the lining of the womb from undue thickening (hyperplasia) by the oestrogen in HRT and the potential for malignant change.
Progestogen almost completely prevents the risks of malignancy. It has been shown that if you take oestrogen replacement therapy together with progestogen, you are even less likely to develop cancer of the endometrium than a lady who has never been on HRT.
Many women who have not yet reached the menopause experience symptom relief with HRT. In general, progestogens are prescribed for ten or twelve days on a sequential basis. A withdrawal (period-like) bleed usually occurs about 2 to 4 days after the progestogen course has been completed. As with the combined pill, the withdrawal bleed with HRT should replace your period and would not be in addition to it.
The choice includes
- a combination of an oestrogen preparation (Figure 28.1 Group A) with a progestogen (Group B),
- or a combination pack with the oestrogen and sequential progestogen (Group C).
Two progestogens have been marketed specifically for combination with an oestrogen. These are
- Micronor HRT (norethisterone 1mg – Janssen-Cilag) and
- Duphaston HRT (Dydrogesterone 10mg - Solvay).
It must be emphasised that these are to be used in combination with an oestrogen – they are not in themselves forms of HRT.
Progesterone gel (Crinone - Serono) can be introduced vaginally every other night from the 15th to the 25th day of the cycle. There are two strengths – 4% and 8%.
- Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. (2004-01)
- Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. (2002-01)
- The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy (2000)
- Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy (1996)
- A dose-ranging study of the use of cyclical dydrogesterone with continuous 17 beta oestradiol (1995)
- The symptomatology of progestogen intolerance (1994).
- Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. (2005-01)
- Long-term effects of two different continuous combined regimens of hormone replacement therapy on well-being. (2004-01)
- Well-being at onset of hormone replacement therapy: comparison between two continuous combined regimens. (2004-02)
- Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. (2001-01)
- Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate (1994)
- Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability.(2007-01)
- Endometrial Effects of Tibolone. (2006-01)
- Effect of different preparations of hormone therapy on sexual dysfunction in naturally postmenopausal women. (2006-02)
- Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study. (2006-03)
- Different effects of tibolone and low-dose EPT in the management of postmenopausal women with primary headaches. (2006-04)
- Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. (2005-01)
- Effect on sexual life--a comparison between tibolone and continuous combined conjugated e quine estrogens and medroxyprogesterone acetate. (2005-02)
- Efficacy and safety of oral tibolone 1.25 or 2.5 mg/day vs. placebo in postmenopausal women. (2003-01)
- Dose-response analysis of effects of tibolone on climacteric symptoms. (2002-01)
- Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy (2001)
- The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. (2000-01)
- A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms (1998-01)
- A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. (1998-02)
- A study of the effect of tibolone on the vagina in postmenopausal women (1994)
- The incidence of vaginal bleeding with tibolone treatment (1994)
- Effect of tibolone on postmenopausal bone loss (1994)
- A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. (2001-01)
- The levonorgestrel intrauterine system in menopausal hormone replacement therapy: Five-year experience. (1999).
- Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. (1998-01)
- increased bone density,
- relief of benign breast disease symptoms,
- enhanced libido and
- relief of premenstrual syndrome.
- Effects and side effects of 2% progesterone cream on the skin of peri- and postmenopausal women: results from a double-blind, vehicle-controlled, randomized study. (2005-01)
- A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women (2000)
- Transdermal Testosterone Gel prn Application for Hypoactive Sexual Desire Disorder in Premenopausal Women: A Controlled Pilot Study of the Effects on the Arizona Sexual Experiences Scale for Females and Sexual Function Questionnaire. (2007-01)
- Sexuality and the menopause. (2006-01)
- Androgen and menopause. (2006-02)
- Androgen insufficiency in women. (2006-03)
- Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. (2006-04)
- A clinical update on female androgen insufficiency--testosterone testing and treatment in women presenting with low sexual desire. (2006-05)
- Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. (2006-06)
- Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. (2006-07)
- Women with low libido: correlation of decreased androgen levels with female sexual function index. (2005-01)
- Androgen deficiency in women (2005-02)
- Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. (2005-03)
- Correlates of circulating androgens in mid-life women: the study of women's health across the nation. (2005-04)
- Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. (2005-05)
- Circulating androgen levels and self-reported sexual function in women. (2005-06)
- Preliminary clinical experience with androgen administration for pre- and postmenopausal women with hypoactive sexual desire. (2005-07)
- Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. (2005-08)
- What is the rationale for androgen therapy for women? (2003-01)
- Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. (2003-02)
- Comparative effects of oral esterified estrogens with and without methyltestosterone on endocrine profiles and dimensions of sexual function in postmenopausal women with hypoactive sexual desire. (2003-03)
- The role of androgen therapy. (2002-01)
- Safety of estrogen/androgen regimens. (2001-01)
- Androgen treatment in women. (1999-01)
- Risks of menopausal androgen supplementation. (1998-01)
- Exogenous androgens in postmenopausal women. (1995-01)
- The role of androgen in the maintenance of sexual functioning in oophorectomized women (1987-01)
- Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause (1985-01)
- We know that HRT reduces hot flushes and night sweats ( 9).
- HRT may overcome local problems including vaginal discomfort and pain during intercourse.
- Some bladder problems may be reduced ( 11).
- HRT may improve menopause-related depression ( Q 27.1) and mental ability ( Q 27.2).
- Heart disease ( Q 27.3) is no longer thought to be reduced
- Osteoporosis ( Q 27.9)
- Alzheimer's disease ( Q 27.2) may be less common in those who have taken HRT.
- Reduces early mortality (death) that might arise as a rise of postmenopausal oestrogen deficiency ( Q 27.25).
- There is an overall reduced risk of cancer ( Q 27.25).
- acne,
- greasy skin and
- rashes or
- depressed mood,
- anxiety,
- aggression and
- panic attacks.
- Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women.(2008-01)
- Unexpected vaginal bleeding and associated gynecologic care in postmenopausal women using hormone replacement therapy: Comparison of cyclic versus continuous combined schedules. (1998)
- clonidine (Dixarit -Boehringer),
- ethamsylate (Dicynene – Delandale) or
- progestogens (Q 24.17B) such as Provera 10 – 30 mg daily
- a blood pressure reading,
- breast and pelvic examination.
- Commencement and maintenance compliance of patients on hormone replacement therapy (HRT) following bilateral oophorectomy (2001)
- Estrogen replacement therapy in practice: Trends and issues (1995)
- A survey of views on hormone replacement therapy (1994)
- 25 mg oestradiol implants - The dosage of first choice for subcutaneous oestrogen replacement therapy? (1992)
- Enhancing patient compliance with hormone replacement therapy at menopause (1990)
- Differences in hormone replacement therapy use by social class, region and psychological symptoms (2001-3340)
- Prevalence and characteristics associated with use of hormone replacement therapy in Britain (1997-1661)
- Utilisation of hormone replacement therapy by women doctors. [see comments] (1995-955)
- Modulation of the oestrogen receptor: A process with distinct susceptible steps. (2000)
- The endometrial effects of SERMs (2000)
- Skeletal effects of selective oestrogen receptor modulators (SERMs). (2000)
- Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. (1998)
- Selective oestrogen receptor modulation: An alternative to conventional oestrogen. (1998)
- Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. (1997)
- Benefits and risks of estrogen replacement therapy (1995)
- Evaluating the benefits and risks of postmenopausal hormone therapy (1991)
- Women's attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey.(2007-01)
- relating personal experiences,
- listening to others' experiences,
- providing sympathetic understanding and
- establishing social networks.
- http://www.climodien.com/html/index.html
- http://www.earlymenopause.com/
- http://www.livial.com/
- http://members. Tripod.com/~HealthInfo/index.html
- http://www. Menopausehysterectomy.com/libido.htm
- http://www.wdxcyber.com/nbleed10.htm

Figure 28.4
The amount of progestogen required varies between individuals. As with any medication one tries to prescribe the lowest amount required to achieve the objective.
Some women have side effects from the progestogen such as premenstrual syndrome type problems.
For some patients it may be necessary to increase the progestogen to prevent light bleeding at inappropriate times. If problems arise, a different progestogen may be considered.
There is one preparation, Tridestra (Orion) which has the progestogen for 14 days but on a three-monthly basis. This has the benefit of three-monthly rather than monthly withdrawal bleeds for women thought to be close to the menopause. Several companies provide packages of oral oestrogen with sequential progestogens (Figure 28.1C; Table 28.5).
Table 28. 5 sequential HRT preparations (cyclical progestogen tablets).
|
PREPARATION |
OESTROGEN/PROGESTOGEN |
mg |
COMPANY |
|
|
TABLETS |
|
|
|
Nuvelle |
Oestradiol / Levonorgestrel |
2 / 75mcg |
Schering |
|
Climagest 1 mg |
Oestradiol / Norethisterone |
1 / 1 |
Novartis |
|
Climagest 2 mg |
|
2 / 1 |
Novartis |
|
Cyclo-Progynova |
Oestradiol / Levonorgestrel |
1 / 0.25 |
Asta |
|
|
Oestradiol / Levonorgestrel |
2 / 0.5 |
Asta |
|
Elleste Duet 1mg |
Oestradiol / Norethisterone |
1/1 |
Searle |
|
Elleste Duet 2mg |
Oestradiol / Norethisterone |
2/1 |
Searle |
|
|
|
|
|
|
Femoston 1/10 |
Oestradiol / Dydrogesterone |
1 / 10 |
Solvay |
|
Femoston 2/10 |
Oestradiol / Dydrogesterone |
12/ 10 |
Solvay |
|
|
|
|
|
|
Prempak-C 0.625 |
Conjugated oestrogens/Norgestrel |
0.625 / 0.15 |
Wyeth |
|
Prempak-C 1.25 |
Conjugated oestrogens/Norgestrel |
1.25 / 0.15 |
Wyeth |
|
Premique Cycle |
Conjugated oestrogens/
Medroxyprogesterone acetate
|
0.625 / 10 |
Wyeth |
|
PREPARATION |
OESTROGEN/PROGESTOGEN |
mg |
COMPANY |
|
|
TRANSDERMAL PATCH + TABLETS |
|
|
|
Estrapak |
Oestradiol / Norethisterone |
50 mcg/ 24hr / 1 |
Ciba |
|
Evorel-Pak |
Oestradiol / Norethisterone |
50 mcg/ 24hr / 1 |
Janssen-Cilag |
|
Femapak 40 |
Oestradiol / Dydrogesterone |
40 mcg/ 24hr / 10 |
Solvay |
|
Femapak 80 |
Oestradiol / Dydrogesterone |
80 mcg/ 24hr / 10 |
Solvay |
Most have a continuous daily amount of oestrogen but Trise quens and Trise quens Forte (Novo Nordisk) have varying amounts of oestrogen designed to imitate the natural cycle.
For those who prefer to avoid tablets there are currently three transdermal patches with sequential progestogen applied during the second half of the cycle (Fig. 28.1 C; Table?28.6).
Table 28. 6 sequential HRT patches.
|
PREPARATION |
OESTROGEN/ PROGESTOGEN |
mg |
COMPANY |
|
Estracombi |
Oestradiol / Norethisterone |
50 mcg + 250mcg/ 24h |
Ciba |
|
Evorel Se qui? |
Oestradiol / Norethisterone |
50 mcg + 170mcg/24 h |
Janssen-Cilag |
|
FemSeven Se qui |
Oestradiol / Levonorgestrel |
50 mcg
10mcg /24 h |
Merck |
|
Nuvelle TS |
Oestradiol / Levonorgestrel |
80 / 50 + 20 mcg /24 h |
Schering |
The Mirena intrauterine system (Mirena), an intrauterine system that slowly releases the progestogen levonorgestrel, offers progestogen protection of the endometrium on a continuous rather than a sequential basis.
This can be introduced before the menopause when it has the benefit of providing contraception and usually reducing menstrual flow. It may also be considered after the menopause for women requiring HRT who cannot tolerate progestogen administered by other routes.
Related Medical Abstracts - Click on the paper title:-
Do all women taking cyclical HRT have withdrawal bleeds?
Nearly 20% of women on sequential regimens will have no bleed and the incidence increases with duration of use.
The number of days of bleeding may diminish with time for those who see regular bleeds.
As with the combined oral contraceptive pill (birth control pill) this is not a reason for anxiety but a variation of a normal response.
Can we adjust the timing of my withdrawal bleeds with HRT for social convenience?
Your doctor can usually advise you how to lengthen the cycle by delaying the progestogen component for a week or two. The packages with varying doses of oestrogen and / or progestogen do not lend themselves to this quite so readily.
Does HRT mean periods again?
Initially when it was realised that unopposed oestrogen in hormone replacement therapy (HRT) could cause problems with the endometrium, progestogens were always administered sequentially even after the menopause. The sequential regimen produced withdrawal bleeds for the majority although a few would have no bleeds. This was, no doubt, a reason for many women deciding against HRT as understandably the idea of monthly withdrawal bleeds was unacceptable for them.
With the arrival of tibolone (Livial; Table 28.7) it became possible to give an HRT preparation to postmenopausal women who still have their womb without causing withdrawal bleeds. Even today, many postmenopausal women are surprised to learn that they can have HRT without enduring withdrawal bleeds.
We now know that it is safe to prescribe any oral (tablets taken by mouth) HRT in combination with a low dose progestogen daily and avoid periods (Figure 28.1).
There are eight tablet preparations and one transdermal patch available for continuous combined HRT (Table 28.7).
A continuous combined vaginal ring is currently being evaluated.

Figure 28.1
Table 28. 7 Continuous Combined HRT preparations.
| PREPARATION |
OESTROGEN/
PROGESTOGEN |
mg | Company |
|
Climesse |
Oestradiol valerate / Norethisterone |
2 / 0.7 |
Novartis |
|
Elleste Duet Conti |
Oestradiol / Norethisterone |
2 / 1 |
Searle |
|
Femoston-Conti |
Oestradiol / Dydrogesterone |
1 / 5 |
Solvay |
|
Kliofem |
Oestradiol /Norethisterone Acetate |
2 / 1 |
Novo Nordisk |
|
Kliovance |
Oestradiol / Norethisterone |
1 / 0.5 |
Novo Nordisk |
|
Livial |
Tibolone |
2.5 |
Organon |
|
Nuvelle Continuous |
Oestradiol / Norethisterone |
2 / 1 |
Schering |
|
Premique |
Conjugated oestrogens / Medroxyprogesterone Acetate |
0.625 / 5 |
Wyeth |
|
|
PATCH |
|
|
|
Evorel Conti |
Oestradiol / Norethisterone |
50/170mcg |
Janssen-Cilag |
|
FemSeven Conti |
Oestradiol / Levonorgestrel |
50/7 |
Merck |
Before the menopause, if a LNG-IUS (Mirena - Mirena) is introduced, to provide endometrial protection for oestrogen replacement therapy, periods tend to be lighter or sometimes they stop.
If you have gone through the menopause and wish to take HRT without having withdrawal bleeds and you cannot tolerate progestogens taken orally or in the patch, the LNG-IUS will provide endometrial protection and may not produce the same side effects.
Some slight spotting of blood is common for the first few weeks and occasionally up to six months with continuous combined HRT. If this should persist or if it occurs later on, the bleeding should be reported to the doctor as investigation is required (hysteroscopy D and C).
Related Medical Abstracts - Click on the paper title:-
What is tibolone (Livial)?
Tibolone is a synthetic steroid that has progestogenic and some androgenic properties (Q 2.9) as well as oestrogenic effects. As it has effects of all three groups of hormones produced by the ovaries (the female gonads) it has been called gonadomimetic. Livial has the advantages of HRT whilst allowing bleed-free HRT for postmenopausal women. There may be irregular bleeding for up to 4-6 months in 10% of patients.
As tibolone has some androgenic effects, from a theoretical point of view it might be expected to improve sexual function and there is some clinical evidence to support this.
There is evidence that Tibolone is less prone to cause irregular bleeding than low dose continuous combined HRT.0701
Related Medical Abstracts - Click on the paper title:-
I have had a premature menopause. What forms of HRT are available to me?
Whereas most postmenopausal women prefer to avoid monthly bleeds, younger women may feel it more natural to see a 'period' and choose to have HRT with a sequential progestogen. Assuming you still have your womb you must have a progestogen in combination with the oestrogen. A spontaneous pregnancy is unlikely but not necessarily impossible. It must be remembered that on occasion there may yet be one or more ova (eggs) that are destined to be released at a later date (8).
Is there a place for the Mirena (LNG-IUS) in the management of the menopause?
The Mirena IUS was launched in theUK
In 1995 for contraception (Mirena). For women approaching the menopause it provides excellent birth control. It provides progestogen protection of the lining of the uterus to be used in conjunction with any form of oestrogen replacement therapy (HRT and progestogen;Figure 28.1B) whether this be by tablet, patch, gel or subcutaneous implant. Before the menopause periods, would usually be absent or light and after the menopause a Mirena would provide one option for HRT without withdrawal bleeds.
Figure 28.1
Related Medical Abstracts - Click on the paper title:-
Progestogen Supplementation
Ovarian failure at the menopause is associated with cessation of progesterone production as well as oestrogen deficiency.
Progest:An American physician, Dr Lee, has described and publicised his experience with ‘natural progesterone cream – ‘ Progest’ - which is applied to the skin. The progesterone is produced in the laboratory from diosgenin by extraction from the Mexican Yam.
Many other reproductive hormones are similarly extracted from the Mexican Yam.
A variety of clinical benefits have been claimed including
Dr Lee recognises the fact that others have used progesterone in capsule form or rectal suppositories (Cyclogest) but he found that the transdermal route was more acceptable for his patients.
There is some evidence that progesterone may have benefit on the heart. Controlled studies are required to confirm the possible advantages of Progest.
One recent study, at King’s
Several patients have come to me wishing to continue Progest having commenced it under the supervision of others. There have been many occasions when patients have not had their symptoms adequately controlled by oestrogen replacement therapy and Progest has apparently helped a few of them.
Related Medical Abstracts - Click on the paper title:-
Is there a place for testosterone replacement?
Tibolone (Livial), an HRT preparation with some
androgenic effect, may increase libido (Livial). Tibolone is available for postmenopausal women or women who have had a hysterectomy.
Testosterone implants have a role for some women with reduced libido or insufficient energy when oestrogen replacement does not suffice.
In one study,8701 five aspects of sexual behaviour were monitored in three groups of women four years after hysterectomy and bilateral salpingo-oophorectomy (removal of both ovaries and the Fallopian tubes) for benign disease. One group received oestrogen replacement only, those in the second group were given a combination of oestrogen and testosterone and the third had no hormone replacement. The rates of coitus (sexual intercourse) and orgasm were highest in the group receiving the oestrogen and testosterone. There was a relationship between the blood levels of testosterone and Frequency of intercourse.
In 1985, various parameters of
sexual functioning were assessed in a study of 53 surgically menopausal
women (the ovaries had been removed).8501
Patients randomly received either an estrogen-androgen combined
preparation, an estrogen-alone drug, an androgen-alone drug, or a
placebo. Also included were a group of women who had undergone
hysterectomy and whose ovaries had been left intact. It was clear that
exogenous androgen enhanced the intensity of sexual desire and arousal
and the Frequency of sexual fantasies in hysterectomized and oophorectomized women. However, there was no evidence that testosterone
affected physiologic response or interpersonal aspects of sexual
behaviour. These findings suggested that the major impact of androgen in
women is on sexual motivation and not on sexual activity per se.
Androgens may be critical
for the maintenance of optimal levels of sexual functioning in
postmenopausal women.8701
Women who are androgen
depleted develop physical and behavioural symptoms referred to as female
androgen deficiency syndrome.9501
To a lesser degree, women who undergo an oophorectomy (ovaries have been
removed) are deprived of endogenous ovarian androgens and have
consistently been shown to have impairment of sexual functioning, loss
of energy, depression, and headaches. Testosterone seems to act
synergistically with estrogen in the treatment of these symptoms. The
combination of estradiol and testosterone has been shown to have a
beneficial effect on the skeleton, although not significantly better
than estradiol therapy alone. Androgen replacement therapy by parenteral
(non-oral) administration to be well tolerated and safe. Such therapy is
underused and very much under-researched.
Potential side effects of chronic
daily testosterone raise questions about this treatment approach.
Chudakov and co-workers0701
hypothesized that a single dose of transdermal testosterone given 4-8
hours prior to planned intercourse in women with hypoactive sexual
desire disorder (HSDD) might increase desire without side effects
associated with chronic use. Premenstrual women with HSDD received eight
packets of gel or identical placebo for use before intercourse twice
weekly for 1 month. For a second month, the alternate treatment was
given. Ten patients completed the study. On the five-item self-report
Arizona, the item "How easily are you aroused?" was significantly
improved on testosterone gel vs. placebo. Further research is required
to define dosage and time schedule to optimize this effect and determine
its clinical relevance.
The
diagnosis of female androgen deficiency syndrome is suggested by
complaints of a diminished sense of well being, persistent unexplained
fatigue and decreased sexual desire, sexual receptivity and pleasure in
a woman who is oestrogen-replete and in whom no other significant
contributing factors can be identified.0605 The diagnosis is supported by the finding of low circulating
concentrations of free testosterone. Barriers to its recognition include
the non-specificity of the symptoms and methodological problems due to
insensitive testosterone assays. Barriers to its treatment include the
unavailability of satisfactory forms of testosterone for administration
to women and lack of data regarding long-term safety. It is important to
recognise that in normal women, androgen levels decline by 50% from the
early 20s to the mid 40s, and hence age-related androgen insufficiency
may occur in women in their late 30s and 40s, as well as
postmenopausally. Satisfactory measurements of free testosterone
requires a sensitive and reliable assay for total testosterone, and
quantification of sex hormone binding globulin, from which free
testosterone is readily calculated. Adverse effects of testosterone
treatment are few if replacement is monitored to achieve physiological
circulating testosterone concentrations. Currently, available methods
include testosterone implants and testosterone creams, and transdermal
patches and sprays are in development.
Testosterone therapy
improves well-being,0302 mood, and sexual function in premenopausal women with low libido and low
testosterone. As a substantial number of women experience diminished
sexual interest and well-being during their late reproductive years,
further research is warranted to evaluate the benefits and safety of
longer-term intervention.
In an Australian,0606
the
efficacy and safety of a testosterone patch in surgically menopausal
women receiving concurrent transdermal estrogen was evaluated. Women who
were using transdermal estrogen, were recruited to a 24-week,
randomized, double-blind, placebo-controlled trial in Europe and
Australia. Forty patients were randomly allocated to placebo or
testosterone 300 microg/day (n = 37) treatment. Sixty-one women (79%)
completed the trial. All subjects who received at least one application
of study medication were included in analysis. The testosterone-treated
group experienced a significantly greater change from baseline in the
domain sexual desire score compared with placebo. The domain scores for
arousal, orgasm, decreased sexual concerns, responsiveness, and
self-image as well as decreased distress were also significantly greater
with testosterone therapy than placebo. The Frequency of satisfactory
sexual events increased but was not statistically different between
treatment groups. Adverse events occurred with similar Frequency in both
groups, and no serious risks of therapy were observed.
Others0503,
0505,
0508,
0509,
0607
have also reported that the testosterone patch increased the Frequency
of satisfying sexual activity and sexual desire, decreased personal
distress, and was well tolerated in menopausal women with
hypoactive sexual desire disorder.
A study by Canadian psychologists,0507 examined the effects of
testosterone on hypoactive sexual desire in pre- and postmenopausal
women compared with an age-matched reference group. Treated participants
received 100 mg of testosterone cypionate in oil injected
intramuscularly monthly for 3 months. They measured salivary
testosterone and scores on the Sexual Desire Inventory pre-treatment and
post-treatment. Treated and reference participants' baseline
testosterone was e quivalent, however, treated participants exhibited
higher testosterone levels than did reference participants
post-treatment. As expected, treated participants exhibited lower
baseline sexual desire than did reference participants and showed a
significant increase in sexual desire post-treatment. This research
suggests that testosterone may effectively alleviate hypoactive sexual
desire, even in women with normal testosterone levels.
The exact role of androgen replacement therapy for
female sexual dysfunction needs further elucidation. In one study,
a single dose of vaginally applied testosterone propionate elevated
serum levels of testosterone and free testosterone within 6 hours.
Nevertheless, this acute rise in androgens had no effects on the female
sexual response.0608
At present, no testosterone preparation has been
approved by the FDA for the treatment of low sexual desire, so
all such therapy is considered to be off-label use at this time. Clear
guidelines regarding the diagnosis of androgen insufficiency, optimal
therapeutic doses, and long-term safety remain lacking.
It is essential that women
should be fully advised before a trial of testosterone treatment.
Related Medical Abstracts - Click on the paper title:-
How would the advantages and disadvantages of HRT compare for me?
This is the key question that applies when considering HRT or, for that matter, any other medical or surgical treatment. You need to weigh up the potential advantages and disadvantages (
Figure 28.2 and
Chapter 27).
Advantages:
Hormone replacement therapy is indicated to treat symptoms that are attributable to oestrogen deficiency.
Reduce long-term morbidity (poor health).
Disadvantages:
No treatment is without potential side effects (Q 28.20)
There can be little doubt that the greatest concern for women considering HRT is breast cancer. The additional risk is very low (Q 27.15).
Similarly, the other potential risk of thrombosis is extremely uncommon (Q 27.22).
The majority of gynaecologists and physicians have believed that for most women the advantages of HRT significantly outweighed the disadvantages. Ultimately it is for you to evaluate the available information and to decide for yourself whether you feel that HRT is the right choice for you. There can be little harm done in putting HRT to the test for a short time.
What side effects could I have with HRT?
Unwanted symptoms can occur with oestrogen and also progestogens if combined regimens are required.
When reproductive hormone levels are changing, women report alterations of feelings that they may find difficult to describe. This may happen in pregnancy, after childbirth and when taking hormones (pill or HRT). Many women feel healthier and happier when pregnant but there is a wide variation. Similarly most women feel better on HRT but others may have a negative reaction.
Oestrogens:
In one study, sixty-one women received either conjugated e quine oestrogens (Premarin) or a placebo (a look-a-like preparation but without the active drug) for six months. The treatment was then reversed for a further six months. The women were not told whether they were taking oestrogen or placebo first (a placebo-controlled study (placebo & controlled trials). Thirteen (21%) reported leg cramps with oestrogens and three (5%) had leg cramps with placebo. Eight (13%) had mastalgia (breast tenderness) with oestrogen but six (10%) had this symptom with the placebo. A few had eye irritation, fluid retention, nausea, vaginal discharge or limb pains. The authors concluded that the incidence of side effects was low and they did not cause any major difficulties for the patients. The leg cramps were difficult to explain but they were not associated with thrombosis (Q4.22).
Progestogens:
There is little data about the incidence of progestogen induced side effects. They may be dose related and differ according to the progestogen used. Symptoms attributable to progestogens are similar to those seen in premenstrual syndrome (Premenstrual Syndrome - PMS).
They may be physical including
psychological with
These side effects can be minimised or abolished for the majority by ensuring that the smallest safe dose is prescribed. If progestogens are taken for only seven days each month the chance of endometrial hyperplasia (thickening) (HRT and progestogen) is only 4%. A change of progestogen (or perhaps progesterone gel Crinone) may be appropriate.
What can be done if I develop irregular bleeding on HRT?
A little irregular bleeding can occur during the first few months of taking HRT. It is likely to settle. Your doctor may wish to check that it is the HRT and there is no other cause for the bleeding. At one time D and C (hysteroscopy D and C) was commonly recommended but these days a tiny tube can be introduced into the cavity of the womb to obtain a small endometrial biopsy (sample) of the lining (Q 24.9). Sometimes the bleeding may settle with additional progestogen for one or two months. There are many HRT preparations and a change to another type or strength may be the solution. We also find that a course of antibiotics may help on occasion, presumably by treating bacteria in the uterine cavity.
Related Medical Abstracts - Click on the paper title:-
Will I gain weight if I start HRT?
A common anxiety amongst women contemplating HRT is weight gain.
There is no evidence, that HRT routinely causes weight gain.
A personal computerised search (Medline ̵ internet information) of the literature revealed twelve publications that looked at the relationship between HRT and weight. There was no difference in weight change whether HRT was taken or not in eight studies. One study indicated a weight loss with HRT and three found a slight increase with the HRT.
In a study conducted in
Related Medical Abstracts - Click on the paper title:-
If I have menopausal symptoms but cannot take HRT what other options are there?
At one time many women were advised that they could not take HRT for a variety of reasons that are no longer considered to be contraindications. Diabetes, high blood-pressure, heart disease and obesity were regarded as medical reasons for avoiding HRT but this is no longer the case. Nowadays, there are very few, if any, absolute contra-indications to HRT.
Some women have anxieties about interfering with hormones or cannot find an HRT preparation that suits them.
For those with hot flushes, hot flashes, night sweats, the following may help.
If the problems relate to vaginal dryness, including discomfort or dyspareunia (pain during intercourse) topical vaginal oestrogen preparations that are poorly absorbed may be considered for vaginal symptoms.
Tamoxifen is frequently prescribed for several years following a diagnosis of breast cancer (Q32.42). This drug has anti-oestrogenic activity, which is probably its mode of action on the breast tumour.
Paradoxically, tamoxifen also has some oestrogenic activity on the genital tract so postmenopausal women taking it seem to be less prone to vaginal symptoms
Examination should include
These examinations are not performed because of any increased risk, but purely as it is good clinical practice for doctors looking after to provide appropriate reassurance.
There is usually no indication to check oestrogen levels routinely for patients having oestrogen replacement therapy. Occasionally, a blood hormone test may assist adjustment of hormone replacement therapy if symptoms persist.
A 48-year-old lady with depression seemed to benefit for a while with transdermal patches but then her depression increased again. Her plasma oestradiol test was found to be low on two occasions. An oestradiol implant was introduced and this resulted in symptomatic relief.
Regular testosterone estimations should be considered for women receiving testosterone treatment (Q 28.18).
Routine breast screening is recommended in most developed countries (Q32.36).
Hormone replacement therapy may be associated with increased glandular tissue making breast x-rays (mammograms) appear denser it is essential that the radiologist reading the pictures is aware that you are on HRT. Sometimes supplementary tests such as ultrasound may be recommended. We advocate regular mammography for postmenopausal women. If you have been taking HRT for more than ten years, mammography once every year or eighteen months would seem appropriate beyond the age of fifty.
At one time, regular sampling of the endometrium (lining of the uterus) was advocated when HRT involved oestrogen without progestogen. We now know that if you are taking oestrogen replacement together with progestogen supplements you are even less likely to develop endometrial cancer than a woman who have never taken HRT. There is, therefore, no longer a reason to recommend sampling unless there is inappropriate bleeding.
How long can I take HRT?
If HRT is being taken only to correct symptoms (e.g. Flushes or headaches), it may be reasonable to stop the HRT after a few months and see whether the symptoms persist.
For long-term prophylaxis (prevention) of osteoporosis, treatment should continue for several years or perhaps indefinitely. The risk is a slight increase in the incidence of breast cancer (by 1.5% from 7.5% without HRT to 9.0% if HRT is taken for more than 15 years Q 27.15).
Do most women continue HRT?
It is now recognised that HRT has been the most important advance in preventative medicine since the introduction of vaccines.
Patient compliance (adherence to treatment) is variable. Great variation in the degree of patient compliance is reported between different centres.
In one study only 40% of those women commencing HRT were taking it reliably after nine months. There were a number of reasons for this. Some were anxious about the possible risks of cancer or they had heard stories that HRT resulted in weight gain (these stories are disproven (Q 28.22). Others were unhappy with side effects such as headaches, 'period' problems or breast discomfort.
How can doctors encourage their patients to continue with our HRT?
Primarily by arriving at decisions in a partnership with our patients.
Each patient must be involved in decisions about her treatment.
Provision of information leaflets that answer key questions allow patients to be kept informed.
Recommending the use of continuous combined preparations to avoid withdrawal bleeds after the menopause and regular review encourages women to enjoy the long-term benefits of HRT.
Doctors should be willing to change preparations if problems arise.
In 1998, a fifty-seven year old health-visitor was referred to me as her withdrawal bleeds were heavy and she felt poorly for the last week of each course of her sequential HRT. Without HRT she felt “hot and bothered". It became apparent that neither the patient nor the general practitioner were aware of continuous combined preparations. A continuous combined preparation was prescribed and she has become “a new woman".
An article in the British Journal of Obstetrics and Gynaecology in 1997 found the information supplied with five HRT preparations was incorrect and misleading. The authors observed that ischaemic (coronary) heart disease, for example, was a contraindication to HRT according to the accompanying information, when the opposite was thought to be true (Q 27.3). Doctors should encourage the pharmaceutical industry to ensure that their data sheets are modified regularly so that the information they provide to patients is accurate.
Related Medical Abstracts - Click on the paper title:-
Are women who have had higher education more likely to take HRT?
A study in Northern Italy found that women who had received formal education for twelve years or more were three times as likely to take hormone replacement therapy compared to those with seven years formal education or less. Most menopausal women doctors in theUnited Kingdom have taken HRT and most of them continue to take it for more than five years.
Related Medical Abstracts - Click on the paper title:-
Are their any new developments with HRT?
Selective oestrogen receptor modulators (SERMs e.g. Evista - Lilly) are being investigated.
These substances selectively produce oestrogenic effects at some sites such as the bones but do not affect other sites such as the breast or endometrium. These new drugs will require a lot more research before we will know enough about their long-term benefits and risks.
Related Medical Abstracts - Click on the paper title:-
What are your conclusions with regard to the risks and benefits with HRT?
For many years we believed the evidence indicated that the benefits outweighed the risks (Q 28.19 –Figure 28.2).
There is debate as to how much the support, understanding and care provided may be assisting patients on HRT but this is true for any treatment.
Most patients attending HRT clinics report tremendous benefits from treatment and the majority of women have no problems with side effects.?
Ultimately it is for each woman to decide for herself, from an unbiased summary of the available information, whether she wishes to commence HRT and then to continue with it.
Related Medical Abstracts - Click on the paper title:-
HRT - What are women's attitudes?
Attitudes vary from country to country, with education status and with media coverage.
The majority of women said they did not know enough about HRT and alternative therapies to make informed choices. There appeared to be many women with vaginal symptoms who had not spoken with a health professional and therefore were untreated.0701
Related Medical Abstracts - Click on the paper title:-
Support Groups:
Members of a support group, provide each other with various types of help and information for a particular shared difficulty.
The support may take the form of providing relevant information,
A support group may also provide ancillary support, such as serving as a voice for the public or engaging in advocacy.
Support groups maintain interpersonal contact among their members in a variety of ways.
Support groups also maintain contact through printed information rich newsletters, telephone chains, internet forums, and mailing lists.
Support groups offer companionship and information for people coping with diseases or disabilities. Support groups may not be appropriate for everyone, and some find that a support group actually adds to their stress rather than relieving it.
Evaluation of the quality of Web sites is discussed in (Q4.27). You may find that several general women's health sites may help you (internet information). The following are more specialised relevant Web sites:-
This page was last updated: April 2008
http://www. Medforum.nl/gynfo/leading2.htm
Androgens:
http://pslgroup.com/dg/34622.htm
http://www. Mja.com. Au/public/issues/jun7/davis/davis.html
This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.
I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.
The aim of this web site is to provide a general
guide and it is not intended as a substitute for a consultation
with an appropriate specialist in respect of individual care and
treatment.
In 1999, he setup this website - www.2womenshealth.com - to provide detailed
information many of his patients requested. The website attracts thousands of visitors every day from around the world.
Website design and search engine optimization became hobies that he plans to pursue in his retirement.
If you would like advice on your website, please visit his website
www.firstwebsitedesign.com or email him on
david@firstwebsitedesign.com.
![]() |
![]() |
![]() |
Join my Google + circle
|









